Related Experiment Video

Updated: Mar 12, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

8.0K

Roles of SIRT3 in heart failure: from bench to bedside

De-Xing Hu1,2,3, Xian-Bao Liu1,2, Wen-Chao Song3

  • 1Department of Cardiology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.

Journal of Zhejiang University. Science. B
|November 8, 2016
PubMed

Insights

Sirtuin 3 (SIRT3) shows promise in preventing heart failure (HF). This mitochondrial deacetylase protects against cardiac hypertrophy and ischemic injury, suggesting SIRT3 agonists could be key for cardiovascular disease prevention.

Area of Science:

  • Cardiovascular Medicine
  • Mitochondrial Biology
  • Biochemistry

Background:

  • Heart failure (HF) is a major global health concern, often resulting from cardiovascular diseases (CVDs).
  • Despite treatment advances, HF prevalence is rising, emphasizing the need for preventative strategies.
  • HF pathogenesis involves contractile dysfunction, cardiac hypertrophy, remodeling, and ischemic injury.

Purpose of the Study:

  • To review the cardioprotective roles of Sirtuin 3 (SIRT3), a mitochondrial NAD+-dependent deacetylase.
  • To explore SIRT3's involvement in cardiac hypertrophy and cardiomyocyte ischemic injury.
  • To discuss the potential of SIRT3 agonists in preventing cardiac hypertrophy and ischemia-reperfusion injury.

Main Methods:

  • Review of existing scientific literature on SIRT3 function in the heart.
  • Analysis of studies investigating SIRT3's role in pressure overload-induced cardiac hypertrophy.
  • Examination of research on SIRT3's effects on cardiomyocytes during ischemic injury.

Main Results:

  • SIRT3 plays a significant role in mitigating cardiac hypertrophy and protecting against ischemic damage.
  • Over-expression or activation of SIRT3 demonstrates cardioprotective effects.
  • SIRT3 regulates metabolic and stress-response proteins within mitochondria.

Conclusions:

  • SIRT3 is a critical factor in maintaining cardiac health and preventing heart failure.
  • Targeting SIRT3 activity, potentially through agonists, offers a promising avenue for therapeutic intervention.
  • Further research into SIRT3 modulation could lead to novel strategies for cardiovascular disease prevention.

Keywords:
Heart failureHypertrophyIschemia reperfusionSIRT3

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
607
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.3K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
455
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
761
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K